Using both molecular and functional studies we demonstrate that treatment with intravenously (IV) injected Ab‐TP‐MDNPs reduces hypoxia, BACE1, VEGF, proinflammatory cytokines, vascular, and lymphatic dysfunction in a transgenic mouse model of AD (TgCRND8). The gene discussed is VEGFA; the disease is Alzheimer disease.